---
document_datetime: 2024-08-27 14:34:39
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pioglitazone-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: pioglitazone-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 4.5481181
conversion_datetime: 2025-12-27 14:28:09.643203
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pioglitazone Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0027              | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site          | 27/06/2023                          | n/a                                         |                                  |           |
| IB/0026              | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 19/12/2022                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0025   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/10/2022   | n/a   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0024/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.4 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Deletion of certificates (in case multiple certificates exist per material) | 20/09/2022   | n/a   |
| IA/0023   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/06/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

| IA/0022     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/01/2022   | 23/01/2023   | Annex II and PL   |     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----|
| II/0020     | Update of the Risk Management Plan (RMP) for the removal of safety concerns and additional risk minimisation measures (ARRM) as per summary of RMP of Glidipion (pioglitazone; published on 20-Jul- 2020), and content adapted to the new GVP Module V (Rev.2). Product information Annex II is amended accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 26/11/2020   | 09/12/2021   | Annex II          | n/a |
| IAIN/0021   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                     | 25/11/2020   | 09/12/2021   | Annex II and PL   |     |
| IAIN/0018/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                     | 25/02/2019   | n/a          |                   |     |

<div style=\"page-break-after: always\"></div>

|           | - Change to importer, batch release and quality control testing of the FP - of a site where batch takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | B.II.b.2.a arrangements Replacement/addition control/testing   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------|
| T/0017    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28/01/2019 | 14/02/2019 | SmPC, Labelling and PL |                                                                |
| IAIN/0016 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                | 27/09/2018 | 14/02/2019 | Annex II and PL        |                                                                |
| II/0015/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 19/04/2018 | n/a        |                        |                                                                |

<div style=\"page-break-after: always\"></div>

|             | the finished or intermediate product - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range   |            |            |                                                                                                                                                                                                                                                                                    |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                      | 05/04/2017 | n/a        |                                                                                                                                                                                                                                                                                    |
| R/0011      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/10/2016 | 05/12/2016 | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pioglitazone Accord in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0013/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                          | 27/10/2016 | n/a        |                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IB/0012/G   | a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   | 28/06/2016   | 05/12/2016   | SmPC and PL           | This was an application for the MAH   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|---------------------------------------|
| IAIN/0010   | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                        | 15/01/2016   | n/a          |                       |                                       |
| IA/0008     | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                 | 02/12/2014   | n/a          |                       |                                       |
| IB/0007     | To update the section 2, 4.1, 4.2, 4.3, 4.4, 4.6, 4.7, 4.8, 5.1, 5.3, 6.6 of SmPC, Annex II and Annex IIIB section 1, 2, 3, 4, 5, 6, in line with originator product information and to add indication no longer under patent. Furthermore, annexes were brought in line with the latest QRD template version. All changes made are in order to harmonise text with the                                                                                                                                                                    | 10/10/2014   | 07/11/2014   | SmPC, Annex II and PL | originator.                           |

<div style=\"page-break-after: always\"></div>

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                                  |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------|
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by           | 12/12/2013 | 07/11/2014 | SmPC and PL                      | the MAH |
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 12/11/2013 | 20/12/2013 | SmPC, Annex II, Labelling and PL |         |
| IAIN/0004 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                | 30/08/2013 | n/a        |                                  |         |
| IAIN/0003 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                     | 22/01/2013 | 20/12/2013 | SmPC, Labelling and PL           |         |
| N/0002    | Minor change in labelling or package leaflet not                                                                                                                                                                                                               | 18/06/2012 | 20/12/2013 | PL                               |         |

<div style=\"page-break-after: always\"></div>

|         | connected with the SPC (Art. 61.3 Notification)                                                                            |            |     |
|---------|----------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001 | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 12/06/2012 | n/a |